Back to the future
Financial overview July-September
- Net sales amounted to
SEK 54.3 M (0.0) -
Operating loss amounted to
SEK 338.9 M (loss: 383.5) -
Loss for the period was
SEK 777.5 M (loss: 383.4) -
Loss per share, before and after dilution, was
SEK 10.33 (loss: 5.71) -
Cash and cash equivalents amounted to
SEK 671.3 M (1,251.6) onSeptember 30
Financial overview January-September
- Net sales amounted to
SEK 140.0 M (0.0) -
Operating loss amounted to
SEK 1,031.1 M (loss: 1,079.7) -
Loss for the period was
SEK 1,036.3 M (loss: 1,081.7) -
Loss per share, before and after dilution, was
SEK 14.27 (loss: 17.87) -
Cash and cash equivalents amounted to
SEK 671.3 M (1,251.6) onSeptember 30
Significant events July-September
- Updated results from the phase 3 OCEAN study were announced on
July 8 : melflufen met the primary endpoint of superior PFS -
FDA requested on
July 8 , a partial clinical hold of all clinical studies with melflufen, based on OS data in the ITT-population -
FDA issued a safety alert to patients and healthcare professionals on
July 28 , regarding an increased risk of death associated with Pepaxto® in the OCEAN study -
FDA announced an ODAC meeting on
September 2 , scheduled forOctober 28 . The meeting was later cancelled -
New data from OCEAN and PORT were presented at the IMW meeting on
September 11
Significant events after the reporting period
Anders Martin-Löf , CFO, resigned fromOncopeptides onOctober 15 -
Pepaxto was withdrawn from the US market on
October 22 and as suchOncopeptides will close commercial operations and refocus on R&D Oncopeptides communicated focused clinical development efforts to increase cash runway onNovember 4 -
Annika Muskantor joined as interim CFO on
November 8 Jakob Lindberg was appointed CEO ofOncopeptides . Marty J Duvall left the company onNovember 15
Financial overview of the Group
(SEK thousand) | 2021 Jul-Sep | 2020 Jul-Sep | 2021 Jan-Sep | 2020 Jan-Sep | 2020 Jan-Dec |
Net sales | 54,276 | - | 140,005 | - | - |
Gross profit | 22,683 | - | 105,262 | - | - |
Gross margin | 42% | N/A | 75% | N/A | N/A |
Operating loss | -338,913 | -383,498 | -1,031,081 | -1,079,706 | -1,591,279 |
Loss after tax | -777,547 | -388,357 | -1,036,327 | -1,081,727 | -1,594,693 |
Earnings per share before and after dilution (SEK) | -10,33 | -5.71 | -14,27 | -17.87 | -25.57 |
Cash flow from operating | -336,528 | -340,841 | -1,069,937 | -939,347 | -1,296,509 |
Cash and cash equivalents at the end of the period | 671,269 | 1,251,629 | 671,269 | 1,251,629 | 840,255 |
R & D costs/operating expenses, % | 41% | 50 % | 44% | 59 % | 54 % |
Conference call for investors, analysts and the media
Investors, financial analysts, and media are invited to participate in a webcast with a QnA at
The webcast will be streamed via this link which can also be found on the website: www.oncopeptides.com.
Phone numbers for participants from:
SE: +46 8 505 583 53
US: +1 833 823 05 89
For more information, please contact:
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28
E-mail: linda.holmstrom@oncopeptides.com
Cell phone: +46 70 873 40 95
This information is information that
About
https://news.cision.com/oncopeptides-ab/r/oncopeptides-publishes-q3-2021-report,c3459305
https://mb.cision.com/Main/15404/3459305/1500560.pdf
https://mb.cision.com/Public/15404/3459305/9e58d785ab73358f.pdf
(c) 2021 Cision. All rights reserved., source